Frank Yocca, Chief Scientific Officer at BioXcel Therapeutics, Inc. (BTAI), sold 29,100 shares at $47.62 ($1.4M) on 2021-01-25, disclosed to the SEC on 2021-01-27.
Open-market sale of $1.4M BTAI by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.94 | 900 | $42K | 3.0% |
| 2 | $47.62 | 3,472 | $165K | 11.7% |
| 3 | $47.62 | 3,472 | $165K | 11.7% |
| 4 | $48.39 | 6,521 | $316K | 22.4% |
| 5 | $48.39 | 6,521 | $316K | 22.4% |
| 6 | $49.35 | 4,107 |
| $203K |
| 14.4% |
| 7 | $49.35 | 4,107 | $203K | 14.4% |
| Total | $48.43 avg | 29,100 | $1.4M | 100% |
| Filing → |
| BTAI | SELL | 2024-10-03 | $4K | — | Filing → |
| BTAI | SELL | 2024-09-17 | $245 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $476 | — | Filing → |